Flivasorb® and Flivasorb® Adhesive Super Absorbent Dressings are comprised of a flexible, non-adherent wound contact layer, highly absorbent gelling fiber core, and a breathable polypropylene outer layer.
• Manages moderate to high volumes of exudate
• Irreversibly binds fluid, even under compression
• Low-profile design is comfortable and works well under bandages
• Highly conformable
• Adhesive and non-adhesive versions available
Flivasorb® and Flivasorb® Adhesive Super Absorbent Dressings are indicated for the management of moderately to highly exuding acute and chronic wounds.
No adverse effects or reactions have been reported.
No storage restrictions.
|Antimicrobial format available|
|Conforms readily to wound|
|Intact when saturated||●|
|Moisture vapor permeable||●|
|Secondary dressing required|
|Usable on infected wounds||●|
|Variety of sizes||●|
|Educational Material Available|
|Free Samples/Trials Available||●|
|Published Clinical Article Available||●|
Moderate/Highly Exudating Wounds
Superficial Second-Degree Burns
Cleanse the wound according to clinical protocols. Pat dry wound edges. Apply Flivasorb® with the contact layer facing toward the wound. Dressing should extend beyond the wound edge by 2cm-3cm. Do not cut Flivasorb®. Secure Flivasorb® non-adhesive version with secondary dressing.
Flivasorb® and Flivasorb® Adhesive Super Absorbent Dressings may remain in place for up to 7 days or until maximum absorption capacity has been reached.
Adhesive secondary dressing such as Suprasorb® F Transparent Film Dressing for the Flivasorb® non-adhesive version.
Blue non-woven outer layer covering absorbent core with gelling fibers over thin and flexible conforming non-adherent wound contact layer. Flivasorb® Adhesive incorporates an adhesive border cover.
L&R USA, Inc. (L&R) is part of a leading global medical device company, which has been delivering high-quality health care products for over 160 years. L&R USA, Inc. is dedicated to providing health care professionals product solutions in the treatment of wounds, edema, venous disease, and lymphedema to improve patient care and outcomes.